股本结构
单位：万股
| 公告日期 | 2024-03-15 | 2024-01-17 | 2024-03-15 | 2023-11-13 | 2023-11-09 | 2023-08-11 |
|---|---|---|---|---|---|---|
| 证券总股本 | 732.92 | 314.61 | 314.61 | 314.61 | 286.40 | 286.37 |
| 普通股本 | 732.92 | 314.61 | 314.61 | 314.61 | 286.40 | 286.37 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-08 | 2024-01-12 | 2023-12-31 | 2023-10-30 | 2023-09-30 | 2023-08-09 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-15 | 732.92 | 未披露 | 定期报告 | 2024-03-08 |
| 2024-01-17 | 314.61 | 未披露 | 定期报告 | 2024-01-12 |
| 2024-03-15 | 314.61 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Settlement of commitment fee
Issuance of common stock upon exercise of warrants
Conversion of convertible notes
Reverse split fractional shares
Public offering, net
Settlement of restricted stock units
|
2023-12-31 |
| 2023-11-13 | 314.61 | 未披露 | 定期报告 | 2023-10-30 |
| 2023-11-09 | 286.40 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-08-11 | 286.37 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-07-14 | 276.98 | 未披露 | 定期报告 | 2023-07-05 |
| 2023-05-12 | 163.36 | 未披露 |
更多>>
Common Stock offered 349,000 shares by the company
|
2023-05-12 |
| 2023-05-12 | 128.46 | 未披露 | 定期报告 | 2023-05-04 |
| 2023-03-30 | 125.21 | 未披露 |
更多>>
On March 28, 2023, Ensysce Biosciences, Inc. filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split of common stock, par value $0.0001.
|
2023-03-31 |
| 2023-03-30 | 1542.56 | 未披露 | 定期报告 | 2023-03-27 |
| 2023-02-24 | 1502.56 | 1.50 | 定期报告 | 2023-02-13 |
| 2023-02-06 | 1502.56 | 未披露 |
更多>>
Common stock offered 3,571,431 shares by the company
|
2023-02-06 |
| 2023-02-06 | 1145.42 | 未披露 | 定期报告 | 2023-02-03 |
| 2023-01-31 | 1145.04 | 未披露 | 定期报告 | 2023-01-26 |
| 2023-03-30 | 641.41 | 未披露 |
更多>>
From December 31, 2021 To December 31, 2022
Consultant compensation
Settlement of restricted stock units
Conversion of convertible notes
Settlement of payable to related parties
Public offering, net
Reverse split fractional shares
|
2022-12-31 |
| 2023-01-03 | 641.41 | 未披露 | 定期报告 | 2022-12-30 |
| 2022-12-19 | 641.33 | 未披露 | 定期报告 | 2022-12-14 |
| 2022-12-09 | 579.33 | 未披露 |
更多>>
Common stock offered 2,280,000 shares by the company
|
2022-12-09 |
| 2022-12-09 | 351.33 | 未披露 | 定期报告 | 2022-12-07 |
| 2022-11-14 | 284.11 | 未披露 | 定期报告 | 2022-11-07 |
| 2022-10-27 | 233.10 | 未披露 |
更多>>
On October 27, 2022, Ensysce Biosciences, Inc. filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-twenty (1-for-20) reverse stock split (the “Reverse Stock Split”) of their common stock, par value $0.0001 (the “Common Stock”). The Reverse Stock Split will be effective as of 12:01 am on October 28, 2022 (the “Effective Time”).
|
2022-10-28 |
| 2022-10-28 | 4662.01 | 未披露 | 定期报告 | 2022-10-24 |
| 2022-08-19 | 3837.79 | 未披露 | 定期报告 | 2022-08-16 |
| 2022-08-11 | 3732.06 | 未披露 | 定期报告 | 2022-08-08 |
| 2022-07-13 | 3649.88 | 未披露 | 定期报告 | 2022-07-07 |
| 2022-08-11 | 3553.03 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Conversion of convertible notes
Settlement of restricted stock units
|
2022-06-30 |
| 2022-05-12 | 3456.10 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-05-02 | 3201.10 | 未披露 | 定期报告 | 2022-04-29 |
| 2022-05-12 | 2994.90 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Consultant compensation
Conversions of convertible notes
Settlement of restricted stock units
|
2022-03-31 |
| 2022-03-31 | 2994.90 | 未披露 | 定期报告 | 2022-03-25 |
| 2022-03-31 | 2464.31 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Settlement of convertible notes in business combination
Conversion of convertible notes
Issuance of common stock for business combination, net of transaction costs
|
2021-12-31 |
| 2021-11-15 | 2425.58 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Stock-based compensation
Issuance of warrants
Warrants modification
|
2021-09-30 |
| 2021-09-22 | 2427.55 | 未披露 | 定期报告 | 2021-09-20 |
| 2021-08-16 | 2425.58 | 未披露 | 定期报告 | 2021-08-13 |
| 2021-07-07 | 2427.55 | 未披露 | 定期报告 | 2021-07-02 |
| 2021-08-16 | 2425.58 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Settlement of convertible notes
Issuance of common stock for business combination, net of transaction costs
|
2021-06-30 |
| 2021-06-08 | 622.43 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Change in value of common stock subject to possible redemption
|
2020-12-31 |
| 2020-08-07 | 626.23 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Change in value of common stock subject to possible redemption
|
2020-06-30 |
| 2020-05-07 | 703.86 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Change in value of common stock subject to possible redemption
|
2020-03-31 |
| 2020-03-10 | 2387.63 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Change in value of common stock subject to possible redemption
|
2019-12-31 |
| 2018-05-03 | 2500.00 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-02-26 | 2500.00 | 未披露 | 定期报告 | 2018-02-26 |
| 2018-03-09 | 2575.00 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Common stock issued to initial stockholders (“Founder Shares”)
Cancellation of Founder Shares
Sale of 20,000,000 Units, net of underwriters discount and offering costs
Common stock subject to redemption
|
2017-12-31 |
| 2017-11-03 | 718.75 | 未披露 | 定期报告 | 2017-09-25 |
From December 31, 2022 to December 31, 2023
Settlement of commitment fee
Issuance of common stock upon exercise of warrants
Conversion of convertible notes
Reverse split fractional shares
Public offering, net
Settlement of restricted stock units
Common Stock offered 349,000 shares by the company
On March 28, 2023, Ensysce Biosciences, Inc. filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split of common stock, par value $0.0001.
Common stock offered 3,571,431 shares by the company
From December 31, 2021 To December 31, 2022
Consultant compensation
Settlement of restricted stock units
Conversion of convertible notes
Settlement of payable to related parties
Public offering, net
Reverse split fractional shares
Common stock offered 2,280,000 shares by the company
On October 27, 2022, Ensysce Biosciences, Inc. filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-twenty (1-for-20) reverse stock split (the “Reverse Stock Split”) of their common stock, par value $0.0001 (the “Common Stock”). The Reverse Stock Split will be effective as of 12:01 am on October 28, 2022 (the “Effective Time”).
From March 31, 2022 to June 30, 2022
Conversion of convertible notes
Settlement of restricted stock units
From December 31, 2021 to March 31, 2022
Consultant compensation
Conversions of convertible notes
Settlement of restricted stock units
From December 31, 2020 to December 31, 2021
Exercise of stock options
Settlement of convertible notes in business combination
Conversion of convertible notes
Issuance of common stock for business combination, net of transaction costs
From June 30, 2021 to September 30, 2021
Stock-based compensation
Issuance of warrants
Warrants modification
From March 31, 2021 to June 30, 2021
Settlement of convertible notes
Issuance of common stock for business combination, net of transaction costs
From December 31, 2019 to December 31, 2020
Change in value of common stock subject to possible redemption
From March 31, 2020 to June 30, 2020
Change in value of common stock subject to possible redemption
From January 1, 2020 to March 31, 2020
Change in value of common stock subject to possible redemption
from December 31, 2018 to December 31, 2019
Change in value of common stock subject to possible redemption
from December 31, 2016 to December 31, 2017
Common stock issued to initial stockholders (“Founder Shares”)
Cancellation of Founder Shares
Sale of 20,000,000 Units, net of underwriters discount and offering costs
Common stock subject to redemption